Guruprasadh Swaminathan
Overview
Explore the profile of Guruprasadh Swaminathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cordero J, Swaminathan G, Rogel-Ayala D, Rubio K, Elsherbiny A, Mahmood S, et al.
Nat Commun
. 2024 Dec;
15(1):10711.
PMID: 39706840
The dynamics of three-dimensional (3D) genome organization are essential to transcriptional regulation. While enhancers regulate spatiotemporal gene expression, chromatin looping is a means for enhancer-promoter interactions yielding cell-type-specific gene expression....
2.
Swaminathan G, Rogel-Ayala D, Armich A, Barreto G
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473229
The eukaryotic genome is mainly transcribed into non-coding RNAs (ncRNAs), including different RNA biotypes, such as micro RNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), among others. Although...
3.
Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer
Rubio K, Romero-Olmedo A, Sarvari P, Swaminathan G, Ranvir V, Rogel-Ayala D, et al.
Theranostics
. 2023 May;
13(8):2384-2407.
PMID: 37215577
Small cell lung cancer (SCLC) is an extremely aggressive cancer type with a patient median survival of 6-12 months. Epidermal growth factor (EGF) signaling plays an important role in triggering...
4.
Kumar A, Singam A, Swaminathan G, Killi N, Tangudu N, Jose J, et al.
Nanoscale
. 2021 Dec;
14(2):492-505.
PMID: 34913453
Cancer is a debilitating disease and one of the leading causes of death in the world. In spite of the current clinical management being dependent on applying robust pathological variables...
5.
Kourani K, Jain P, Kumar A, Jangid A, Swaminathan G, Durgempudi V, et al.
Nanomedicine
. 2021 Dec;
40:102504.
PMID: 34890821
This study reports the development and pre-clinical evaluation of biodrug using RNA interference and nanotechnology. The major challenges in achieving targeted gene silencing in vivo include the stability of RNA...
6.
Rawoof A, Swaminathan G, Tiwari S, Nair R, Kumar L
Database (Oxford)
. 2020 Mar;
2020.
PMID: 32128558
Acute lymphoblastic leukemia (ALL) is one of the most common hematological malignancies in children. Recent studies suggest the involvement of multiple microRNAs in the tumorigenesis of various leukemias. However, until...